Effect of antacids on predicted steady-state cimetidine concentrations.
The purpose of this study was to evaluate effects of antacids on predicted steady-state concentrations of cimetidine. Ten healthy volunteers received in random order one week apart, cimetidine and cimetidine and antacid suspension. Blood was obtained at specified times and analyzed for cimetidine. Bioavailability was assessed by comparison of peak concentration, time to peak concentration, area under the curve, and time spent over 0.5 micrograms/ml. Single-dose data were extrapolated to steady-state using computer simulation. Concurrent administration of antacid suspension reduced parameters of bioavailability approximately 30%. When steady-state conditions were simulated, concentrations of cimetidine greater than or equal to 0.5 micrograms/ml were maintained for the entire dosing interval in seven of 10 subjects. These data suggest that temporal separation of cimetidine and antacid suspension may be unnecessary.
D000328:Adult; D000536:Aluminum Hydroxide / Q000378:metabolism*; D001682:Biological Availability; D002927:Cimetidine / Q000097:blood* / Q000378:metabolism; D004338:Drug Combinations / Q000378:metabolism; D004347:Drug Interactions; D006801:Humans; D008274:Magnesium / Q000378:metabolism*; D008276:Magnesium Hydroxide / Q000378:metabolism*; D008297:Male; D012828:Silicones / Q000378:metabolism*; D012841:Simethicone / Q000378:metabolism*
D004338:Drug Combinations; D012828:Silicones; C008570:aluminum hydroxide, magnesium hydroxide, simethicone drug combination; D000536:Aluminum Hydroxide; D002927:Cimetidine; D012841:Simethicone; D008274:Magnesium; D008276:Magnesium Hydroxide